Open AccessPosition S tatement on the management of continuous subcutaneous insulin infusion ( CSII ): The Italian Lazio experience
Author(s) -
Maurizi Anna R.,
Suraci Concetta,
Pitocco Dario,
Schiaffini Riccardo,
Tubili Claudio,
Morviducci Lelio,
Giordano Renato,
Manfrini Silvia,
Lauro Davide,
Frontoni Simona,
Pozzilli Paolo,
Buzzetti Raffaella
Publication year - 2016
Publication title -
journal of diabetes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.949
H-Index - 43
eISSN - 1753-0407
pISSN - 1753-0393
DOI - 10.1111/1753-0407.12321
Subject(s) - medicine , reimbursement , glycemic , insulin , insulin pump , type 1 diabetes , diabetes mellitus , intensive care medicine , diabetes management , health care , type 2 diabetes , endocrinology , economics , economic growth
This document has been developed by a group of Italian diabetologists with extensive experience in continuous subcutaneous insulin infusion ( CSII ) therapy to provide indications for the clinical management of CSII in diabetic patients (both type 1 and type 2) based on delivery mode operating in I taly. Although the potential benefits of pump therapy in achieving glycemic goals is now accepted, such results cannot be obtained without specific knowledge and skills being conveyed to patients during ad hoc educational training. To ensure that these new technologies reach their full effectiveness, as demonstrated theoretically and clinically, a careful assessment of the overall therapeutic and educational process is required, in both qualitative and quantitative terms. Therefore, to ensure the cost‐effectiveness of insulin pump therapy and to justify reimbursement of therapy costs by the N ational H ealth S ystem in I taly, in this article we present a model for diabetes and healthcare centers to follow that provides for different levels of expertise in the field of CSII therapy. This model will guarantee the provision of excellent care during insulin pump therapies, thus representing the basis for a successful outcome and expansion of this form of insulin treatment in patients with diabetes while also keeping costs under control.